The therapeutic strategy of inhibiting VEGF in HCC has evolved not only to target angiogenesis but also to alleviate immunosuppressive mechanisms, thereby synergistically enhancing the effect of ICIs. This evidence concerns the gene VEGFA and hepatocellular carcinoma.